Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?

Bailly, Christian; Vergoten, Gérard

Bailly, Christian; Vergoten, Gérard.

Affiliation

Bailly C; OncoWitan, Lille, Wasquehal 59290, France. Electronic address: christian.bailly@oncowitan.com.
Vergoten G; University of Lille, Inserm, U995 - LIRIC - Lille Inflammation Research International Center, ICPAL, 3 rue du Professeur Laguesse, BP-83, F-59006 Lille, France.

Pharmacol Ther ; 214: 107618, 2020 10.

Article in En | MEDLINE | ID: mdl-32592716

Subject(s)

Coronavirus Infections/drug therapy; Glycyrrhizic Acid/pharmacology; Glycyrrhizic Acid/therapeutic use; Pneumonia, Viral/drug therapy; Alarmins/drug effects; Betacoronavirus; COVID-19; Coronavirus Infections/epidemiology; Drug Therapy, Combination; Humans; Hydroxychloroquine/therapeutic use; Membrane Microdomains/drug effects; Molecular Docking Simulation; Pandemics; Pneumonia, Viral/epidemiology; SARS-CoV-2; Tenofovir/therapeutic use; COVID-19 Drug Treatment

Key words

COVID-19; Cholesterol; Coronavirus; Glycyrrhizin; HMGB1; Natural product

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Glycyrrhizic Acid Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Pharmacol Ther Year: 2020 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google